Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) for the Evaluation of Response to Therapy in Bone-dominant Metastatic Breast Cancer

NCT01996046 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT01996046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01996046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) for the Evaluation of Response to Therapy in Bone-dominant Metastatic Breast Cancer
Lead sponsor
University of Pennsylvania
Phase
Observational
Overall status
Completed
Start date
September 30, 2013
Completion date
July 31, 2026
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, estrogen receptor positive breast cancer